Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: Asthmatics affected by obesity have a higher risk of asthma attacks and longer hospital stays than non-obese asthmatics...
Read Full NewsComplicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.
The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.
1.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Second opinions don't significantly delay breast cancer treatment
4.
Researchers study effects of cannabis on sedation, cancer treatment symptoms
5.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
1.
Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound
2.
Beyond Immunotherapy: Emerging Novel Treatments for Small Cell Lung Cancer
3.
Exploring Dyscrasias: Uncovering the Causes and Treatments of Unusual Blood Disorders
4.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
5.
IL1R2 Inhibition: A New Strategy to Boost Cancer Immunity
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
5.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge